Brief period of ischemia and reperfusion has been reported to protect the heart against subsequent ischemia and reperfusion, and this phenomenon is known as early ischemic preconditioning.
Brief period of ischemia and reperfusion has been reported to protect the heart against subsequent ischemia and reperfusion, and this phenomenon is known as early ischemic preconditioning. 1) In the most experimental models, activation of protein kinase C (PKC) by stimulation of adenosine A 1 receptors 2, 3) and/or G q -coupled receptors, such as a 1 -adrenergic receptor, bradykinin B 2 receptor, and angiotensin II AT 1 receptor, appears to be involved in the mechanism of preconditioning. [4] [5] [6] [7] We 8, 9) and other laboratories [10] [11] [12] previously reported that p38 mitogen-activated protein (MAP) kinase is a very important molecule for the underlying mechanism. However, the signal molecules between PKC and p38 MAP kinase have been still unclear. Reorganization of actin cytoskeleton after translocation of HSP27, which is mediated by p38 MAP kinase, was reported to be necessary for the cardioprotective effect of early ischemic preconditioning by us 8, 9) and others. 11, 13) Rho and Rho kinase are reported to regulate reorganaization of actin filaments through the ezrin/radixin/moesin system. 14, 15) Rho kinase is reported to be activated by 12-O-tetradecanoylphorbol 13-acetate (TPA), a PKC activator, 16) and to regulate the activity of Na ϩ -H ϩ exchanger, 17) which has a close relationship with ischemiareperfusion injury. 18) In addition, stimulation of a 1B -adrenergic receptor is recently reported to activate p38 MAP kinase via G q , 19) and Rho is reported to be required for G q and a 1 -adrenergic receptor signaling in cardiomyocytes. 20) Therefore, it is of interest to examine whether Rho-Rho kinase pathway is involved in the cardioprotective effect of early ischemic preconditioning. The aim of the present study is to determine the involvement of Rho-Rho kinase pathway in the protective effect of early ischemic preconditioning in the rat hearts.
MATERIALS AND METHODS

Cell Culture, Transfecion and Hypoxia-Reoxygenation
Rat myoblast H9c2 cells (American Type cell culture collection) were grown as a monolayer in Dulbecco's-modified Eagle medium with 10% fetal bovine serum (FBS). The cells were cultured at 37°C in a humidified atmosphere containing 5% CO 2 . Complementary DNAs of HA-human p38 MAP kinase, dominant negative RhoA (FLAG-RhoAT19N), constitutive active RhoA (FLAG-RhoAG14V), and constitutive active Rac1 (FLAG-Rac1G12V), which were inserted into pCMV5 expression vector, were kindly provided by Dr. Junji Yamauchi (National Research Institute for Child Health and Development, Tokyo, Japan), Dr. Gozo Tsujimoto (Kyoto University, Kyoto, Japan), and Dr. Hiroshi Itoh (Nara Institute of Science and Technology, Nara, Japan). Plasmid DNA was transfected into H9c2 cells by LipofectAMINE TM reagent (Invitrogen, Carlsbad, CA, U.S.A.) according to manufacturer's instruction. One microgram of pCMV5-human p38 MAP kinase was co-transfected with 1 mg pCMV5 empty vector, 1 mg pCMV5-FLAG-RhoAT19N, 1 mg pCMV5-FLAG-RhoAG14V or 1 mg pCMV5-FLAGRac1G12V. The cells were used for experiments 24 h after the transfection procedure. The method for preconditioning hypoxia-reoxygenation stimulation is described previously.
10)
The cells were subjected to 10 min of hypoxia and 15 min of reoxygenation for preconditioning.
Immunoprecipitation and Immunobloting Cells were washed with ice-cold phosphate buffered saline (PBS), lysed with radio immunoprecipitation assay (RIPA) buffer, comprised of 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS) in PBS. Cell lysate were mixed with anti-HA (12CA5) (Roche, Basel, Switzerland) and rotated for 12 h at 4°C. Thereafter, protein G-Sepharose 4FF (Amersham, Piscataway, NJ, U.S.A.) was added to the lysate, and rotated for 1 h at 4°C. The immunecomplexes were precipitated by centrifugation, washed 4 times with RIPA buffer, and boiled in Laemmli SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer. The boiled samples were separated by SDS-PAGE with 10% polyacrylamide gel, and the proteins were transferred to polyvinylidene difluoride (PVDF) membrane (Biorad, Hercules, CA, U.S.A.). After the membranes were blocked with 1% bovine serum albumin (BSA) and 0.1% Tween 20 in PBS, phospho-p38 MAP kinase and HA-tagged p38 MAP kinase were probed with antiphospho-p38 MAP kinase antibody (Promega, Madison, WI, U.S.A.) and anti-HA antibody, respectively.
Isolated Rat Heart Experiment In the present study, experimental procedures conform to the Guiding Principles for the Care and Use of Laboratory Animals approved by the Japanese Pharmacological Society, and the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996). Male Sprague-Dawley rats (250-350 g) were anesthetized with pentobarbital sodium (50 mg/kg, intraperitoneally (i.p.)). Their hearts were rapidly excised and immersed in ice-cold modified Krebs-Henseleit buffer solution (KHB), comprising (in mM) NaCl 118, KCl 4.7, CaCl 2 1.5, MgSO 4 1.2, KH 2 PO 4 1.2, NaHCO 3 25 and glucose 10, in an atmosphere of 95%O 2 -5%CO 2 . After contraction had ceased, the hearts were cannulated via aorta, perfused retrogradely with KHB at a constant flow of 18 ml/min, placed in the chamber, which was filled with KHB, and maintained at 37°C.
In order to measure the left ventricular pressure, a latex balloon filled with distilled water was inserted via the left atrium into the left ventricular cavity and inflated so that the left ventricular end diastolic pressure was adjust to 5-10 mmHg. The balloon was connected to a pressure transducer (DX-100, Ohmeda Singapore, Singapore). The transducer was connected to carrier amplifier (AP-621G, Nihon Kohden, Tokyo, Japan) to obtain pressure pulse. The first derivative of the left ventricular pressure (LV dP/dt) was calculated by pressure processor (EQ-601G, Nihon Kohden). Heart rate was recorded by a heart rate counter (AT-601G, Nihon Kohden) and triggered by the left ventricular pressure pulse. The left ventricular developed pressure (LVDP) was calculated as the difference between the left ventricular systolic and diastolic pressures.
The six experimental groups employed were: control (nϭ5), 10 mM Y-27632 (Sigma-RBI, St. Louis, MO, U.S.A.)-treated without early ischemic preconditioning (nϭ5), early ischemic preconditioning (nϭ6), 1 mM Y-27632-treated plus early ischemic preconditioning (nϭ5), 3 mM Y-27632-treated plus early ischemic preconditioning (nϭ5) and 10 mM Y-27632-treated plus early ischemic preconditioning (nϭ5). All the hearts were perfused for 15 min equilibration period, after which they were perfused for 10 min in the presence or absence of Y-27632. For early ischemic preconditioning, the hearts were subjected to one cycle of 5 min of global ischemia and 5 min reperfusion in the presence or absence of Y-27632. Y-27632 was added to the perfusate to produce final concentration from a 10 mM stock solution made up in distilled water. This period was followed by global ischemia by stop the aortic flow for 25 min and reperfusion for 30 min.
Statistical Analysis Each datum is expressed as a meanϮS.E.M. Paired or Student's t-test was used to compare two means. One way analysis of variance followed by Tukey-Kramer post-hoc test was used for multiple comparisons. Differences were considered to be statistically significant when the p value was less than 0.05. Figure 1 illustrates the relationship between the activation of p38 MAP kinase induced by preconditioning stimulation and Rho in H9c2 cells. Preconditioning stimulation, consisting of 4 cycles of 5 min of hypoxia and 5 min of reoxygenation, clearly activated p38 MAP kinase, and transient expression of dominant-negative RhoA significantly reduced the activation of p38 MAP kinase. In addition, transient expression of constitutive-active RhoA, but not Rac1, significantly activated p38 MAP kinase in normoxic condition. Therefore, we propose that Rho is an upstream enzyme of p38 MAP kinase in the signal transduction of early ischemic preconditioning in the rat hearts. In order to examine this possibility, the following examinations were designed.
RESULTS AND DISCUSSION
Activation of p38 MAP Kinase Induced by Preconditioning Stimulation and Rho
Y-27632 Atenuates the Protection against IschemiaReperfusion Injury by Early Ischemic Preconditioning
The contractile functions before preconditioning ischemia were similar for all the groups in the present study ( Figs. 2A-E). Early ischemic preconditioning significantly reduced left ventricular developed pressure and the maximum value of the first derivative of the left ventricular pressure (LV dP/dt max ), and tended to decrease rate pressure product just before 25 min of ischemia compared to the control hearts. The concentrations of Y-27632, a specific Rho kinase inhibitor, used in the present study did not affect left ventricular developed pressure, LV dP/dt max , and RPP before 25 min of ischemia. Heart rate before 25 min of ischemia was not altered by any treatment. At the end of reperfusion, left ventricular developed pressure, LV dP/dt max and rate pressure product did not recover in the control group (Figs. 2E-H) . The pre-ischemic treatment of 10 mM Y-27632 slightly enhanced the recovery of left ventricular developed pressure, LV dP/dt max and rate pressure product at the end of reperfusion. This result is consistent with the previous report, which shows treatment of Y-27632 reduced the infarction induced by ischemia-reperfusion in the rat hearts. 21) Early ischemic preconditioning significantly improved the recovery of left pCMV5-HA-p38 MAP kinase vector was co-transfected with pCMV5-RhoAT19N, pCMV5-RhoAG14V or pCMV5-Rac1G12V to the cells. The cells with or without hypoxia-reoxygenation were lysed with RIPA buffer, and phosphor-p38 MAP kinase was detected as described in Material and Methods. The gel images are the representative ofventricular developed pressure, LV dP/dt max and rate pressure product at the end of reperfusion. Though 1 mM Y-27632 did not alter the cardioprotective effect of early ischemic preconditioning, 3 or 10 mM Y-27632 abolished the recovery of left ventricular developed pressure, LV dP/dt max and rate pressure product by early ischemic preconditioning. Except the early ischemic preconditioning and the 1 mM Y-27632-treated plus early ischemic preconditioning groups, ventricular fibrillation occurred during reperfusion; 1 heart in the control, 1 heart in the 10 mM Y-27632-treated without early ischemic preconditioning, 3 hearts in the 3 mM Y-27632-treated plus early ischemic preconditioning and 2 hearts in the 10 mM Y-27632-treated plus early ischemic preconditioning group. Except the hearts in which ventricular fibrillation occurred, heart rate was almost the same as the value before early ischemic preconditioning.
The results we showed in the present study are inconsistent with those of a previous report by Demiryürek et al. 21) Since they used only a single dose of Y-27632 (0.1 mg/kg), it is possible that they could not observe the inhibitory effect of Y-27632 on the cardioprotective effect by early ischemic preconditioning because of an insufficient dose of the drug. Previous studies proposed that PKC d 22) and PKC e 23) were involved in the mechanism of early ischemic preconditioning. Although Y-27632 has been reported to inhibit PKC d 24) and PKC e , 25) the IC 50 value of the drug for PKC d is more than 30 mM, and the affinity for PKC e is 10-50-fold lower than that for Rho-associated protein kinase. Therefore, the results in the present study suggest that Rho-Rho kinase pathway is involved in cardioprotection induced by early ischemic preconditioning.
Possible Mechanism of Cardiac Protection by Early Is- chemic Preconditioning Mediated by Rho-Rho Kinase Pathway We previously demonstrated that cardioprotection by early ischemic preconditioning was blocked by SB203580, a specific p38 MAP kinase inhibitor, in rat myoblast cells and beating hearts. 8, 9) Other laboratories also reported that early ischemic preconditioning increased the phosphorylation of p38 MAP kinase in the rabbit heart. [10] [11] [12] We and the other laboratory are shown that anisomycin, an activator of p38 MAP kinase, mimicked cardioprotection by early ischemic preconditioning. 9, 10) Therefore, p38 MAP kinase has a very important role in signal transduction of early ischemic preconditioning. In the present study, repetitive hypoxia-reoxygenation led to the activation of p38 MAP kinase, and transient expression of dominant-negative Rho reduced the activation of the kinase. Transient expression of constitutive-active Rho increased the phosphorylation of p38 MAP kinase. Rho has been shown to be activated by ischemia-reperfusion. 26) In addition, Y-27632 inhibited cardioprotection by early ischemic preconditioning in the rat perfused hearts. Therefore, it is possible that the phophorylation of p38 by early ischemic preconditioning is mediated by Rho.
In the most experimental models, activation of PKC by stimulation of G q -coupled receptors appears to be involved in the mechanism of early ischemic preconditioning. [2] [3] [4] [5] [6] [7] 9) In H9c2 cells, protection against hypoxia-reoxygenation by phorbol ester, a PKC activator, was blocked by SB203580, 27) a specific p38 MAP kinase inhibitor. We previously reported that the cardioprotective effect of 2-chloro-N 6 -cyclo-pentyladenosine, which is an adenosine A 1 receptor agonist and known to activate PKC, 3) is blocked by SB203580. 9) These previous reports strongly suggest that p38 MAP kinase is a very important downstream molecule from PKC in signal transduction of early ischemic preconditioning. Rho has been reported to be required for G q and a 1 -adrenergic receptor signaling in cardiomyocytes. 20) Stimulation of a 1B -adrenergic receptor is reported to activate p38 MAP kinase via G q , 19) and the active form of G q is shown to activate p38 MAP kinase via Rho and mitogen-activated protein kinase kinase 6 (MKK6) in HEK293 cells. 28) Based on these reports, we propose that early ischemic preconditioning stimulation activates PKC via G q -coupled receptors followed by activation of Rho and Rho kinase, and then p38 MAP kinase is phosphorylated via MKK6. However, it is possible that Rho and Rho kinase is activated by early ischemic preconditioning stimulation without relation to the PKC pathway. Further experiments are needed to confirm our hypothesis.
CONCLUSION
We have demonstrated that transient expression of dominant-negative RhoA reduced the activation of p38 MAP kinase by early ischemic preconditioning, which is a very important step in signal transduction of early ischemic preconditioning, [8] [9] [10] [11] [12] and transient expression of constitutive-active RhoA activated p38 MAP kinase in the rat myoblast cell line, H9c2. The protective effect of early ischemic preconditioning was reduced by Y-27632, a specific Rho kinase inhibitor. Therefore, Rho-Rho kinase pathway may contribute to the protective effect of early ischemic preconditioning in the heart.
